Mr. Gan · haixiao@sungolytest.com · +86 158 2169 5110 · +86 132 4819 8029Mr. Luo · jun.luo@sungoglobal.com · +86 177 5560 4650

QWT

Prognostic Assessment Software Of Mild Cognitive Impairment

Product code
QWT
Device name
Prognostic Assessment Software Of Mild Cognitive Impairment
Device class
Class 2
21 CFR
21 CFR 882.1454
Medical specialty
Neurology
Marketing pathway
510(K)
510(k) clearances (last 3 years)
1
Summaries archived here
0 (direct download)
510(k) clearances (all years, FDA)
1 (all years; only the last 3 years are listed here)

FDA classification definition

Prognostic assessment software of mild cognitive impairment. Prognostic assessment software of mild cognitive impairment is a prescription-only device that combines information from multiple clinical data sources to produce an output indicative of the likelihood that a patient diagnosed with mild cognitive impairment will progress to more severe forms of cognitive impairment, or will develop dementia, such as Alzheimer’s disease dementia, within a specified period of time. This device is intended for adjunctive use and not intended as a stand-alone diagnostic or prognostic too.

Definition text from the FDA device classification database (U.S. federal government work, public domain).

510(k) clearances, last 3 years (1)

Last three years. Most recent: 2024-01-11.

NumberDecision dateApplicantDevice nameSummary
DEN2200662024-01-11Darmiyan, Inc.BrainSee—
Official FDA classification page: QWT
Classification and pathway per current FDA publications. Data from openFDA (CC0).